Characterization of human soluble high and low activity catechol-O-methyltransferase catalyzed catechol estrogen methylation

Pharmacogenetics

Volumn 12, Issue 7, 2002, Pages 517-528

  Goodman, Julie E ^a   Jensen, Laran T ^a   He, Ping ^a   Yager, James D ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Catechol O methyltransferase polymorphism; Estrogen; Kinetics

Indexed keywords

CATECHOL ESTROGEN; CATECHOL METHYLTRANSFERASE; S ADENOSYLMETHIONINE;

ALLELE; ARTICLE; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CELL LINE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME KINETICS; ESTROGEN METABOLISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; METHYLATION; MICHAELIS MENTEN KINETICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; STOICHIOMETRY;

BASE SEQUENCE; BREAST; CATALYSIS; CATECHOL O-METHYLTRANSFERASE; CLONING, MOLECULAR; CYTOSOL; DNA PRIMERS; EPITHELIAL CELLS; ESCHERICHIA COLI; ESTROGENS, CATECHOL; FEMALE; HUMANS; KINETICS; METHYLATION; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; S-ADENOSYLMETHIONINE; SUBSTRATE SPECIFICITY;

ESCHERICHIA COLI;

EID: 0036797599     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200210000-00003     Document Type: Article

References (52)

1. Axelrod J, Senoh S, Witkop B. O-Methylation of catecholamines in vivo. J Biol Chem 1958; 233:697-701.
2. Mannisto PT, Ulmanen I, Lundstrom K, Taskinen J, Tenhunen J, Tilgmann C, et al. Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 1992; 39:291-350.
3. Cohn CK, Dunner DL, Axelrod J. Reduced catechol-O-methyltransferase activity in red blood cells of women with primary affective disorder. Science 1970; 170:1323-1324.
4. Weinshilboum RM, Raymond FA. Inheritance of low erythrocyte catechol-O-methyltransferase activity in man. Am J Hum Genet 1977; 29:125-135.
5. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996; 6:243-250.
6. Creveling CR, Inoue K. Catechol-O-methyltransferase: factors relating to the carcinogenic potential of catecholestrogens. Polycyclic Aromatic Compounds 1994; 6:253-259.
7. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998; 19:1-27.
8. Yager JD. Chapter 3: endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 2000; 27:67-73.
9. Yim D-S, Park SK, Yoo K-Y, Yoon K-S, Chung HH, Kang HJ, et al. Relationship between the val158met polymorphism of catechol O-methyl transferase and breast cancer. Pharmacogenetics 2001; 11:1-8.
10. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 1999; 59:4870-4875.
11. Lavigne JA, Helzlsouer KJ, Huang HY, Strickland PT, Bell DA, Selmin O, et al. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 1997; 57:5493-5497.
12. Millikan RC, Pittman GS, Tse CK, Duell E, Newman B, Savitz D, et al. Catechol-O-methyltransferase and breast cancer risk. Carcinogenesis 1998; 19:1943-1947.
13. Thompson PA, Shields PG, Freudenheim JL, Stone A, Vena JE, Marshall JR, et al. Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res 1998; 58:2107-2110.
14. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, et al. Polymorphic catechol-O-methyltransferase gene and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10:635-640.
15. Bergman-Jungestrom M, Wingren S. Catechol-O-methyltransferase (COMT) gene polymorphism and breast cancer risk in young women. Br J Cancer 2001; 85:859-862.
16. Xie DW, Dai Q, Yager JD, Deng ZL, Shu XO, Wen WQ, et al. Genetic Polymorphisms of catechol-O-methyltransferase and the risk of breast cancer: The Shanghai Breast Cancer Study. Proc Am Ass Cancer Res 1999; 40:567-568.
17. Hamajima N, Matsuo K, Tajima K, Mizutani M, Iwata H, Iwase T, et al. Limited association between a catechol-O-methyltransferase (COMT) polymorphism and breast cancer risk in Japan. Int J Clin Oncol 2001; 6:13-18.
18. Lundstrom K, Tenhunen J, Tilgmann C, Karhunen T, Panula P, Ulmanen I. Cloning, expression and structure of catechol-O-methyltransferase. Biochim Biophys Acta 1995; 1251:1-10.
19. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, et al. Kinetics of human soluble and membrane-bound catechol-O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995; 34:4202-4210.
20. Zhu BT, Liehr JG. Inhibition of the catechol-O-methyltransferase-catalyzed O-methylation of 2- and 4-hydroxyestradiol by catecholamine: implications for the mechanism of estrogen-induced carcinogenesis. Arch Biochem Biophys 1993; 304:248-256.
21. Zhu BT, Liehr JG. Inhibition of catechol O-methyltransferase-catalyzed O-methylation of 2- and 4-hydroxyestradiol by quercetin. Possible role in estradiol-induced tumorigenesis. J Biol Chem 1996; 271:1357-1363.
22. Roy D, Weisz J, Liehr JG. The O-methylation of 4-hydroxyestradiol is inhibited by 2-hydroxyestradiol: implications for estrogen-induced carcinogenesis. Carcinogenesis 1990; 11:459-462.
23. Ball P, Knuppen R, Breuer H. Purification and properties of a catechol-o-methyltransferase of human liver. Eur J Biochem 1971; 21:517-525.
24. Ball P, Knuppen R, Haupt M, Breuer H. Kinetic properties of a soluble catechol O-methyltransferase of human liver. Eur J Biochem 1972; 26:560-569.
25. Dawling S, Roodi N, Mernaugh RL, Wang X, Parl FF. Catechol-o-methyltransferase (comt)-mediated metabolism of catechol estrogens: comparison of wild-type and variant comt isoforms. Cancer Res 2001; 61:6716-6722.
26. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
27. Nissinen E, Mannisto P. Determination of catechol-O-methyltransferase activity by high- performance liquid chromatography with electrochemical detection. Anal Biochem 1984; 137:69-73.
28. Lavigne JA, Goodman JE, Fonong T, Odwin S, He P, Roberts DW, et al. The effects of catechol-O-methyltransferase inhibition on estrogen metabolite and oxidative DNA damage levels in estradiol-treated MCF-7 cells. Cancer Res 2001; 61:7488-7494.
29. Grossman MH, Szumlanski C, Littrell JB, Weinstein R, Weinshilboum R. Electrophoretic analysis of low and high activity forms of catechol-O-methyltransferase in human erythrocytes. Life Sci 1992; 50:473-480.
30. Lundstrom K, Salminen M, Jalanko A, Savolainen R, Ulmanen I. Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol 1991; 10:181-189.
31. Vidgren J, Tilgmann C, Lundstrom K, Liljas A. Crystallization and preliminary X-ray investigation of a recombinant form of rat catechol O-methyltransferase. Proteins 1991; 11:233-236.
32. Tenhunen J, Salminen M, Lundstrom K, Kiviluoto T, Savolainen R, Ulmanen I. Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem 1994; 223:1049-1059.
33. Bertocci B, Miggiano V, Da Prada M, Dembic Z, Lahm HW, Malherbe P. Human catechol-O-methyltransferase: cloning and expression of the membrane-associated form. Proc Natl Acad Sci USA 1991; 88:1416-1420.
34. Malherbe P, Bertocci B, Caspers P, Zurcher G, Da Prada M. Expression of functional membrane-bound and soluble catechol-O- methyltransferase in Escherichia coli and a mammalian cell line. J Neurochem 1992; 58:1782-1789.
35. Ueland PM. Pharmacological and biochemical aspects of S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase. Pharmacol Rev 1982; 34:223-253.
36. Assicot M, Contesso G, Bohuon C. Catechol-O-methyltransferase in human breast cancers. Eur J Cancer 1977; 13:961-966.
37. Hoffman AR, Paul SM, Axelrod J. Catecholestrogen synthesis and metabolism by human breast tumors in vitro. Cancer Res 1979; 39:4584-4587.
38. Tenhunen J, Heikkila P, Alanko A, Heinonen E, Akkila J, Ulmanen I. Soluble and membrane-bound catechol-O-methyltransferase in normal and malignant mammary gland. Cancer Lett 1999; 144:75-84.
39. Lautala P, Ulmanen I, Taskinen J. Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. Mol Pharmacol 2001; 59:393-402.
40. Ball P, Knuppen R, Haupt M, Breuer H. Interactions between estrogens and catechol amines III. Studies on the methylation of catechol estrogens, catechol amines and other catechols by the catechol-O-methyltransferase of human liver. J Clin Endocrinol 1972; 34:736-746.
41. Zhu BT, Roy D, Liehr JG. The carcinogenic activity of ethinyl estrogens is determined by both their hormonal characteristics and their conversion to catechol metabolites. Endocrinology 1993; 132:577-583.
42. Merriam GR, MacLusky NJ, Picard MK, Naftolin F. Comparative properties of the catechol estrogens, I: methylation by catechol-O-methyltransferase and binding to cytosol estrogen receptors. Steroids 1980; 36:1-11.
43. Raxworthy MJ, Gulliver PA. 2-hydroxyethynyloestradiol as a substrate for catechol-O-methyltransferase-implications in the metabolism of ethynyloestradiol. J Steroid Biochem 1982; 17:17-21.
44. Zhu BT, Bui QD, Weisz J, Liehr JG. Conversion of estrone to 2- and 4-hydroxyestrone by hamster kidney and liver microsomes: implications for the mechanism of estrogen-induced carcinogenesis. Endocrinology 1994; 135:1772-1779.
45. Zhu BT, Patel UK, Cai MX, Conney AH. O-Methylation of tea polyphenols catalyzed by human placental cytosolic catechol-O-methyltransferase. Drug Metab Dispos 2000; 28:1024-1030.
46. Zhu BT, Ezell EL, Liehr JG. Catechol-O-methyltransferase-catalyzed rapid O-methylation of mutagenic flavonoids. Metabolic inactivation as a possible reason for their lack of carcinogenicity in vivo. J Biol Chem 1994; 269:292-299.
47. Wagner J, Claverie N, Danzin C. A rapid high-performance liquid chromatographic procedure for the simultaneous determination of methionine, ethionine, S-adenosylmethionine, S-adenosylethionine, and the natural polyamines in rat tissues. Anal Biochem 1984; 140:108-116.
48. Ueland PM, Aarbakke J, Bessesen A. Characterization of S-adenosylhomocysteine binding to isolated rat hepatocytes and purified rat liver plasma membranes. Effect of analogues of S-adenosylhomocysteine. Mol Pharmacol 1982; 21:108-113.
49. Garner CE, Burka LT, Etheridge AE, Matthews HB. Catechol metabolites of polychlorinated biphenyls inhibit the catechol-O-methyltransferase-mediated metabolism of catechol estrogens. Toxicol Appl Pharmacol 2000; 162:115-123.
50. Boudikova B, Szumlanski C, Maidak B, Weinshilboum R. Human liver catechol-O-methyltransferase pharmacogenetics. Clin Pharmacol Ther 1990; 48:381-389.
51. Weinshilboum RM. Human erythrocyte catechol-O-methyltransferase: correlation with lung and kidney activity. Life Sci 1978; 22:625-630.
52. Li SA, Purdy RH, Li JJ. Variations in catechol O-methyltransferase activity in rodent tissues: possible role in estrogen carcinogenicity. Carcinogenesis 1989; 10:63-67.